Induction regimens in older patients with AML
Study . | No. . | Median age, y (range) . | CR, % . | Survival . | Induction death, % . |
|---|---|---|---|---|---|
| Goldstone et al4 | |||||
| DAT | 328 | —* | 62 | 18† | 16 |
| ADE | 327 | —* | 50 | 15 | 26 |
| MAC | 656 | —* | 55 | 16 | 17 |
| Anderson et al25 | |||||
| AD | 161 | 68 (56-84) | 43 | 19‡ | 15 |
| ME | 167 | 67 (56-86) | 43 | 11 | 19 |
| Juliusson et al26 | |||||
| CCI | 43 | 70 (64-75) | 51 | > 30§ | 12 |
| CI | 20 | 73 (65-77) | 35 | — | 10 |
| Rowe et al27 ¶ | |||||
| DA | 116 | 67 (56-82) | 40 | 5.7∥ | —22 |
| IA | 118 | 68 (56-86) | 43 | 9.4 | — |
| MA | 114 | 69 (56-84) | 46 | 7.1 | — |
Study . | No. . | Median age, y (range) . | CR, % . | Survival . | Induction death, % . |
|---|---|---|---|---|---|
| Goldstone et al4 | |||||
| DAT | 328 | —* | 62 | 18† | 16 |
| ADE | 327 | —* | 50 | 15 | 26 |
| MAC | 656 | —* | 55 | 16 | 17 |
| Anderson et al25 | |||||
| AD | 161 | 68 (56-84) | 43 | 19‡ | 15 |
| ME | 167 | 67 (56-86) | 43 | 11 | 19 |
| Juliusson et al26 | |||||
| CCI | 43 | 70 (64-75) | 51 | > 30§ | 12 |
| CI | 20 | 73 (65-77) | 35 | — | 10 |
| Rowe et al27 ¶ | |||||
| DA | 116 | 67 (56-82) | 40 | 5.7∥ | —22 |
| IA | 118 | 68 (56-86) | 43 | 9.4 | — |
| MA | 114 | 69 (56-84) | 46 | 7.1 | — |
DAT indicates daunorubicin, cytarabine, thioguanine; ADE, daunorubicin, cytarabine, etoposide; MAC, mitoxantrone, cytarabine; AD, cytarabine, daunorubicin; ME, mitoxantrone, etoposide; CCI, cladribine, cytarabine, idarubicin; CI, cytarabine, idarubicin; DA, daunorubicin, cytarabine; IA, idarubicin, cytarabine; MA, mitoxantrone, cytarabine; and—, not available.
The median age for the entire group was 66 years (range, younger than 56 to 80).
Five-year disease-free survival (DFS) (%).
2-year overall survival (%).
2-year overall survival (%) for the whole group of patients.
Median DFS in months.